Charles Bennett to Costs and Cost Analysis
This is a "connection" page, showing publications Charles Bennett has written about Costs and Cost Analysis.
Connection Strength
1.163
-
Pricing, profits and pharmacoeconomics--for whose benefit? Expert Opin Pharmacother. 2001 Mar; 2(3):377-83.
Score: 0.173
-
Health economics in the treatment of colorectal cancer. Cancer Invest. 1998; 16(8):582-7.
Score: 0.139
-
Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist. 2007 Aug; 12(8):1019-26.
Score: 0.067
-
Cost considerations in the management of cancer in the older patient. Oncology (Williston Park). 2007 Jun; 21(7):851-7; discussion 858, 860, 862 passim.
Score: 0.067
-
Local perspective of the impact of the HIPAA privacy rule on research. Cancer. 2006 Jan 15; 106(2):474-9.
Score: 0.061
-
Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited. Pharmacoeconomics. 2005; 23(8):767-75.
Score: 0.056
-
Pharmacoeconomics of liposomal anthracycline therapy. Semin Oncol. 2004 Dec; 31(6 Suppl 13):191-5.
Score: 0.056
-
Cost analyses of granulocyte colony stimulating factor: a focus on older patients with cancer. Crit Rev Oncol Hematol. 2003 Oct 15; 48(Suppl):S71-4.
Score: 0.052
-
Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making? Drugs Aging. 2003; 20(7):479-83.
Score: 0.049
-
Clinical trials: are they a good buy? J Clin Oncol. 2001 Dec 01; 19(23):4330-9.
Score: 0.046
-
Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest. 2001; 19(2):107-13.
Score: 0.043
-
Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol. 2000 Feb; 34(2):92-6.
Score: 0.040
-
The potential for treatment of idiopathic thrombocytopenic purpura with anti-D to prevent splenectomy: a predictive cost analysis. Semin Hematol. 2000 Jan; 37(1 Suppl 1):26-30.
Score: 0.040
-
Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999 Sep; 24(5):555-60.
Score: 0.039
-
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients. Cancer Invest. 1999; 17(8):559-65.
Score: 0.037
-
Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs. Urology. 1997 Feb; 49(2):218-24.
Score: 0.033
-
Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest. 1997; 15(3):227-36.
Score: 0.032
-
Economic analysis during phase III clinical trials: who, what, when, where, and why? Oncology (Williston Park). 1995 Nov; 9(11 Suppl):169-75.
Score: 0.030
-
Economics of Malignant Gliomas: A Critical Review. J Oncol Pract. 2015 01; 11(1):e59-65.
Score: 0.028
-
Economic analysis in phase III clinical cancer trials. Cancer Invest. 1994; 12(3):336-42.
Score: 0.026
-
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med. 1992 Feb 01; 116(3):177-82.
Score: 0.023
-
Purchasing oncology services. Kerr L. White Institute/American Cancer Society Task Force on Purchasing Oncology Services. Cancer. 2000 Jun 15; 88(12):2876-86.
Score: 0.010
-
Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know? Bone Marrow Transplant. 1998 Apr; 21(7):641-50.
Score: 0.009
-
Estimating the cost effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia. Pharmacoeconomics. 1996 Jun; 9(6):525-34.
Score: 0.008